Stock Track | Exact Sciences Plummets 7.25% in Pre-Market as Analysts Cut Price Targets on Growth Concerns

Stock Track

2025/02/20

Exact Sciences (EXAS) stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.

Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating.

Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies. Despite the positive ratings from analysts, the price target cuts suggest a more cautious outlook on the stock's valuation and growth potential.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1135485001"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135485001\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135485001?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135485001","market":"us","top_or_hot":-1,"title":"Stock Track | Exact Sciences Plummets 7.25% in Pre-Market as Analysts Cut Price Targets on Growth Concerns","media":"Stock Track","content":"<p>Exact Sciences (EXAS) stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.</p>\n\n<p>Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating.</p>\n\n<p>Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies. Despite the positive ratings from analysts, the price target cuts suggest a more cautious outlook on the stock's valuation and growth potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Exact Sciences Plummets 7.25% in Pre-Market as Analysts Cut Price Targets on Growth Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Exact Sciences Plummets 7.25% in Pre-Market as Analysts Cut Price Targets on Growth Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Exact Sciences (EXAS) stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.</p>\n\n<p>Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating.</p>\n\n<p>Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies. Despite the positive ratings from analysts, the price target cuts suggest a more cautious outlook on the stock's valuation and growth potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"","article_id":"1135485001","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135485001","pubTimestamp":1740062625,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Exact Sciences  stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学"},"translate_title":"分析师因增长担忧下调目标价，Exact Sciences股价盘前暴跌7.25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"Exact Sciences (EXAS) stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.\nBarclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating.\nAdditionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies. Despite the positive ratings from analysts, the price target cuts suggest a more cautious outlook on the stock's valuation and growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}